Revive Therapeutics Ltd.

Revive Therapeutics Advances Bucillamine Research for Nerve Agent Countermeasure in Collaboration with Canadian Defense Agency

- Revive Therapeutics is conducting an ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure in collaboration with Defence R&D Canada – Suffield Research Centre. - The study focuses on evaluating pharmacological compounds that may mitigate nerve agent-induced brain injury, with final findings pending authorization from the Canadian Department of National Defence agency. - Revive Therapeutics is a specialty life sciences company that prioritizes drug development efforts to leverage FDA regulatory incentives including Emergency Use Authorization and Breakthrough Therapy designations. - The company is also exploring Bucillamine for long COVID treatment while advancing development programs for Psilocybin and molecular hydrogen therapeutics.